"Invasive pneumococcal disease remains the most common invasive infection and poses a significant burden. Pneumococcal diseases, such as pneumonia or ear infection, pose significant burden. The new vaccine must cover conventional serotypes as well as newly introduced serotypes to manage the invasive pneumococcal infection and expect an additional reduction."

The introduction of the pneumococcal vaccine with the most serotypes in South Korea has brought attention to its preventive effects against pneumococcus and unmet needs for vaccines.

Given the availability of vaccines in the National Immunization Program (NIP), there is a heightened interest in the preventive effects of added serotypes.<